Ferric carboxymaltose (Ferinject®) associated hypophosphataemia: case report illustrating the need for increased awareness to minimise incidence and risk.

Fisher, Stacey and Jonker, Leon Ferric carboxymaltose (Ferinject®) associated hypophosphataemia: case report illustrating the need for increased awareness to minimise incidence and risk. Acute Medicine Journal .

[img]
Preview
PDF - Accepted Version
Available under License CC BY-NC-ND

Download (230kB) | Preview

Abstract

Ferric carboxymaltose (Ferinject®) is an infusion administered for the treatment of iron deficiency anaemia. A number of previous case reports have shown the occurrence of hypophosphataemia after Ferinject® treatment, supposedly managed though high dose phosphate therapy. This case report highlights the risk associated with, and futility of, managing this adverse effect through high dose phosphate infusion. A review of the available literature suggests that if hypophosphataemia develops as a result of Ferinject®, through upregulation of the renal protein Fibroblast Growth Factor-23, it cannot be readily reversed and on average persists for circa 50 days. Acute medical units should be aware of this – likely underreported – adverse effect, and avoid treating these hypophosphataemic patients with high dose phosphate since it can compound symptoms.

Item Type: Article
Journal / Publication Title: Acute Medicine Journal
Publisher: Rila Publishing
ISSN: 1747-4892
Related URL(s):
Departments: Departments > Institute of Health > Medical Sciences
Depositing User: Christian Stretton
Date Deposited: 26 Aug 2020 12:27
Last Modified: 26 Aug 2020 14:11
URI: https://insight.cumbria.ac.uk/id/eprint/5669

Downloads

Downloads per month over past year



Downloads each year

Actions (repository staff only)

Edit Item Edit Item